Skip to main content
Top
Published in: Annals of Hematology 8/2015

01-08-2015 | Original Article

Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause

Authors: J. Gebhart, C. Laczkovics, F. Posch, C. Ay, S. E. Reitter-Pfoertner, H. Haslacher, L. Muszbek, A. S. Wolberg, I. Pabinger

Published in: Annals of Hematology | Issue 8/2015

Login to get access

Abstract

In a large proportion of patients with mild bleeding disorders (MBDs) no diagnosis can be established by routine coagulation tests. We investigated whether alterations in plasma clot properties account for MBDs of unknown cause. Ninety-five patients with MBDs of unknown origin and 98 age- and sex-matched healthy controls were investigated. Furthermore, data of 25 patients with a deficiency of factor VIII were analyzed. Plasma clot characteristics in the absence and presence of recombinant tissue plasminogen activator (rtPA) represented by the lag phase, rate of protofibril formation (Vmax), fibrin structure (ΔAbs), time to peak (TTP), half lysis time (t50 and area under the curve (AUC) were measured in turbidometric clot formation and lysis assays. In the fibrinolysis assay, Vmax was lower in patients than in healthy controls. No differences in the other parameters of clot formation and lysis were detected between the groups. There was no clear association of plasma clot properties with the clinical severity of bleeding in patients with MBDs. Patients with known decreased factor VIII levels also showed a lower Vmax. Fibrinogen levels were positively associated with each of the assessed parameters in both groups, with the strongest association with ΔAbs, indicating altered fibrin structure. Factor VIII activity correlated with altered clot characteristics similar to fibrinogen, especially in patients, with the strongest positive correlation to Vmax. This cohort of patients with MBDs of unknown origin showed a lower rate of fibrin formation in the fibrinolysis assay, but otherwise similar plasma clot properties compared to healthy controls.
Literature
2.
go back to reference Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76:535–540PubMed Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76:535–540PubMed
5.
go back to reference Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K (2008) Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196:551–557. doi:S0021-9150(07)00381-4 Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K (2008) Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196:551–557. doi:S0021-9150(07)00381-4
6.
go back to reference Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, Tracz W (2009) Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114:4272–4278. doi:blood-2009-010.1182/blood-2009-05-222380 Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, Tracz W (2009) Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114:4272–4278. doi:blood-2009-010.1182/blood-2009-05-222380
7.
go back to reference Antovic A, Mikovic D, Elezovic I, Zabczyk M, Hutenby K, Antovic JP (2014) Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand. Thromb Haemost 111:656–661. doi:10.1160/TH13-06-0479 PubMedCrossRef Antovic A, Mikovic D, Elezovic I, Zabczyk M, Hutenby K, Antovic JP (2014) Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand. Thromb Haemost 111:656–661. doi:10.​1160/​TH13-06-0479 PubMedCrossRef
10.
go back to reference He S, Blomback M, Jacobsson Ekman G, Hedner U (2003) The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 1:1215–1219PubMedCrossRef He S, Blomback M, Jacobsson Ekman G, Hedner U (2003) The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 1:1215–1219PubMedCrossRef
12.
go back to reference Haselboeck J, Panzer S, Janig F, Kepa S, Mannhalter C, Pabinger I (2013) Characterization of adult patients with a mild to moderate bleeding phenotype from the Vienna Bleeding Biobank. ISTH meeting abstracts No. PB 2.41-4 Haselboeck J, Panzer S, Janig F, Kepa S, Mannhalter C, Pabinger I (2013) Characterization of adult patients with a mild to moderate bleeding phenotype from the Vienna Bleeding Biobank. ISTH meeting abstracts No. PB 2.41-4
14.
go back to reference Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A (2005) The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 3:2619–2626. doi:10.1111/j.1538-7836.2005.01663.x PubMedCrossRef Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A (2005) The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 3:2619–2626. doi:10.​1111/​j.​1538-7836.​2005.​01663.​x PubMedCrossRef
15.
go back to reference Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L (2000) A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 46:1946–1955PubMed Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L (2000) A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 46:1946–1955PubMed
16.
go back to reference Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR (2010) Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116:113–121. doi:10.1182/blood-2010-02-267740 PubMedCrossRef Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR (2010) Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116:113–121. doi:10.​1182/​blood-2010-02-267740 PubMedCrossRef
17.
go back to reference Carr ME Jr, Hermans J (1978) Size and density of fibrin fibers from turbidity. Macromolecules 11:46–50PubMedCrossRef Carr ME Jr, Hermans J (1978) Size and density of fibrin fibers from turbidity. Macromolecules 11:46–50PubMedCrossRef
19.
go back to reference Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R (1994) Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75:521–538PubMedCrossRef Blomback B, Carlsson K, Fatah K, Hessel B, Procyk R (1994) Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75:521–538PubMedCrossRef
20.
go back to reference Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW (1994) Changes in clot deformability—a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 5:7CrossRef Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW (1994) Changes in clot deformability—a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 5:7CrossRef
21.
go back to reference Blomback B (1994) Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res 75:327–328PubMedCrossRef Blomback B (1994) Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res 75:327–328PubMedCrossRef
22.
go back to reference Omarova F, Uitte De Willige S, Ariens RA, Rosing J, Bertina RM, Castoldi E (2013) Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen gamma’. J Thromb Haemost 11:1669–1678. doi:10.1111/jth.12354 PubMedCrossRef Omarova F, Uitte De Willige S, Ariens RA, Rosing J, Bertina RM, Castoldi E (2013) Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen gamma’. J Thromb Haemost 11:1669–1678. doi:10.​1111/​jth.​12354 PubMedCrossRef
23.
go back to reference Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, Phoenix F, Gamlen T, Ariens RA, Grant PJ, Ajjan RA (2012) Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 97:E2282–E2287. doi:10.1210/jc.2012-2128 PubMedCrossRef Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, Phoenix F, Gamlen T, Ariens RA, Grant PJ, Ajjan RA (2012) Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab 97:E2282–E2287. doi:10.​1210/​jc.​2012-2128 PubMedCrossRef
28.
30.
go back to reference Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, Allan P, Mohan S, Tans G, Ten Cate H, Ariens RA (2011) Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 118:3942–3951. doi:10.1182/blood-2011-03-339572 PubMedCrossRef Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, Allan P, Mohan S, Tans G, Ten Cate H, Ariens RA (2011) Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 118:3942–3951. doi:10.​1182/​blood-2011-03-339572 PubMedCrossRef
Metadata
Title
Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause
Authors
J. Gebhart
C. Laczkovics
F. Posch
C. Ay
S. E. Reitter-Pfoertner
H. Haslacher
L. Muszbek
A. S. Wolberg
I. Pabinger
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2399-7

Other articles of this Issue 8/2015

Annals of Hematology 8/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.